Adults aged 18 to 45 years who have facial acne, may qualify for this clinical research trial and receive investigational injected vaccine treatment (active study drug) or placebo.

Eligible participants must have a clinical diagnosis of moderate or severe facial acne vulgaris, with 25 or more non-inflammatory lesions (i.e. open and closed comedones – blackheads and whiteheads), 20 or more inflammatory lesions (i.e. papules and pustules), and no more than 2 nodulocystic lesions (i.e. nodules and cysts).  Individuals must refrain from use of any other acne treatments for the duration of the study.

Participants will have regular visits with an experienced research team.  There is no cost to participate, and participants will be reimbursed for study-related expenses.  Depending on which cohort a participant is assigned to, they will be asked to visit the study centre about 14 to 18 times over a period of about 9 to 11 months.

Please complete the form below to see if you are eligible for this trial.

If you have any questions/queries regarding this trial please email | [email protected]